Trials / Recruiting
RecruitingNCT07000682
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UTAA91 injection | CAR-modified gamma delta T cells |
Timeline
- Start date
- 2025-05-30
- Primary completion
- 2027-12-01
- Completion
- 2040-01-01
- First posted
- 2025-06-03
- Last updated
- 2025-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07000682. Inclusion in this directory is not an endorsement.